Overview

Comparison of Biphasic Insulin Aspart 30 Versus Insulin Glargine Both in Combination With Metformin and Glimepiride in Subjects With Type 2 Diabetes

Status:
Completed

Trial end date:
2008-04-01

Target enrollment:

Participant gender:

Summary

This trial is conducted in Africa, Asia, Europe, Oceania and South America. This trial aims for a comparison of biphasic insulin aspart 30 once daily versus insulin glargine once daily all in combination with metformin and glimepiride in insulin naive subjects with type 2 diabetes.

Phase:

Phase 4

Details

Lead Sponsor:

Novo Nordisk A/S

Treatments:

Biphasic Insulins
Glimepiride
Insulin
Insulin Aspart
Insulin aspart, insulin aspart protamine drug combination 30:70
Insulin degludec, insulin aspart drug combination
Insulin Glargine
Insulin, Globin Zinc
Insulin, Isophane
Insulin, Long-Acting
Metformin